Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 inhibitor that Co. discovered through the application of its DCE Platform® (deuterated chemical entity platform). Co. is evaluating CTP-543 in a Phase 3 clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. In addition to its wholly-owned development programs, Co. has entered into collaborative arrangements with companies to develop deuterium-modified versions of their marketed products. We show 37 historical shares outstanding datapoints in our CNCE shares outstanding history coverage, used to compute CNCE market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CNCE market cap history over the course of time is important for investors
interested in comparing CNCE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CNCE versus a peer is one thing; comparing
CNCE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CNCE can fluctuate over the course of history.
With this page we aim to empower investors researching CNCE by allowing them to research the CNCE market cap history. |
Free CNCE Email Alerts:
Video: The Importance of Market Cap
